October 30, 2025 — Leads & Copy — Edwards Lifesciences (NYSE: EW) announced today that its chief financial officer, Scott Ullem, will transition from his role by midyear 2026, enabling continuity and a smooth transfer of responsibilities. Ullem will continue in an advisory role after a new CFO is appointed.
Edwards Lifesciences is a global structural heart innovation company focused on improving patient lives through breakthrough technologies and partnerships.
Forward-looking statements involve risks and uncertainties detailed in the company’s filings with the Securities and Exchange Commission, available at Edwards.com.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation.
Source: Edwards Lifesciences
